---
title: "U.S. stock night market opening fluctuations: Quhuo fell 12.03% in the night market; Diginext fell 11.03% in the night market"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288189930.md"
description: "Quhuo fell 12.03% in the night session; Diginext fell 11.03% in the night session; Lisata Therapeutics rose 34.15% in the night session; Replimune rose 22.90% in the night session; Scinai Immunotherapeutics rose 22.22% in the night session"
datetime: "2026-06-01T00:22:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288189930.md)
  - [en](https://longbridge.com/en/news/288189930.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288189930.md)
---

# U.S. stock night market opening fluctuations: Quhuo fell 12.03% in the night market; Diginext fell 11.03% in the night market

**U.S. Stock Night Market Opening Movements**

Quhuo fell 12.03% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.

Diginext fell 11.03% in the night market. Based on recent key news:

1.  On May 29, Diginex announced an extension of the acquisition agreement deadline with Resulticks. The company and the seller agreed to extend the deadline from May 29 to June 12, which may raise market uncertainty regarding the completion time of the transaction, leading to a decline in stock price.
    
2.  On May 29, the U.S. Securities and Exchange Commission released documents involving Diginex's information disclosure. The document is the responsibility of Diginex and may raise investor concerns about the company's transparency, further affecting the stock price.
    
3.  No other significant news recently. The market is skeptical about the progress of the acquisition, leading to increased volatility.
    

**Top Gaining Stocks in the U.S. Night Market**

Lisata Therapeutics rose 34.15% in the night market. Based on recent key news:

1.  On May 29, Lisata Therapeutics revised its merger offer to $4 per share plus CVR. Following this announcement, the stock price surged significantly.
    
2.  On May 29, Lisata Therapeutics released relevant information through the EDGAR system, further confirming the details of the merger offer and boosting market confidence.
    
3.  No other significant news recently. The increase in the merger offer has led to a positive market reaction.
    

Replimune rose 22.90% in the night market. Based on recent key news:

1.  On May 29, Replimune announced an agreement with the FDA to resubmit its melanoma drug RP1's approval application, which had previously been rejected twice. The FDA indicated it would prioritize the review of this application, boosting investor confidence, and the stock price surged 74% in pre-market trading. Source: Reuters
    
2.  On May 30, the company announced plans to resubmit the FDA approval application for RP1, and following this news, the stock price surged 86% during the trading session. This development is seen as a signal of a shift in the FDA's review stance, further boosting market sentiment. Source: Zhitong Finance
    
3.  On May 31, Replimune presented the first human data of RP2 in advanced solid tumors at the 2026 American Society of Clinical Oncology Annual Meeting, further enhancing market confidence in the company's R&D capabilities. Source: GlobeNewswire The biotechnology industry has recently performed strongly, with significant impacts from FDA approval dynamics.
    

Scinai Immunotherapeutics rose 22.22% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation

### Related Stocks

- [QH.US](https://longbridge.com/en/quote/QH.US.md)
- [DGNX.US](https://longbridge.com/en/quote/DGNX.US.md)
- [LSTA.US](https://longbridge.com/en/quote/LSTA.US.md)
- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)
- [SCNI.US](https://longbridge.com/en/quote/SCNI.US.md)

## Related News & Research

- [Diginex extends long stop date for Resulticks acquisition to June 30](https://longbridge.com/en/news/290049177.md)
- [Stride (LRN) Stock Could Be 62.4% Overvalued After Texas Contract Loss](https://longbridge.com/en/news/290253190.md)
- [LFS: Record Q1 revenue and profit reflect robust growth in social and sports school segments](https://longbridge.com/en/news/290272743.md)
- [Amazon Plans $10B Missouri Data Center Campus](https://longbridge.com/en/news/290258573.md)
- [OMRON Healthcare Completes Tender Offer for Matsuya R&D Shares](https://longbridge.com/en/news/289897181.md)